Skip to main content
MSF logo
  • Media room
  • Contact
  • msf.org
  • MSF Access
    • About MSF Access
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Our work
    • Diabetes
    • Drug-resistant infections
    • Hypertension
    • Patents and intellectual property
      • Pandemic prevention, preparedness and response
      • The Patent Oppositions Database
    • Research and development
      • Spotlight on: the Big Pharma double-dip
      • Transparency Matters: Clinical Trials Costs
    • Tuberculosis
    • Vaccines
    • Other work
      • COVID-19
      • Hepatitis C
      • HIV/AIDS
      • Tropical and neglected diseases
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Get involved
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • A Fair Shot
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    • Recent campaigns
      • Time for $5
      • No Patents in a Pandemic
      • Share the Tech - Save Lives
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Resources
    • Press releases
    • Statements
    • Letters
    • Opinion articles
    • Feature stories
    • Interviews
    • Blog
    • Newsletters
    • Publications
    • Research articles
    • Topic overview pages
    • Videos
    • Photo stories
    • Infographics
    • Events
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Media room
  • Contact
  • msf.org
  • MSF Access
    • About MSF Access
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Our work
    • Diabetes
    • Drug-resistant infections
    • Hypertension
    • Patents and intellectual property
      • Pandemic prevention, preparedness and response
      • The Patent Oppositions Database
    • Research and development
      • Spotlight on: the Big Pharma double-dip
      • Transparency Matters: Clinical Trials Costs
    • Tuberculosis
    • Vaccines
    • Other work
      • COVID-19
      • Hepatitis C
      • HIV/AIDS
      • Tropical and neglected diseases
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Get involved
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • A Fair Shot
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    • Recent campaigns
      • Time for $5
      • No Patents in a Pandemic
      • Share the Tech - Save Lives
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Resources
    • Press releases
    • Statements
    • Letters
    • Opinion articles
    • Feature stories
    • Interviews
    • Blog
    • Newsletters
    • Publications
    • Research articles
    • Topic overview pages
    • Videos
    • Photo stories
    • Infographics
    • Events
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
Medicines shouldn’t be a luxury Take action
Get involved
Our campaigns

Latest Press Releases

Latest Press Releases

Image of bedaquiline, TB drug at the MSF project in Osh, Kyrgyzstan, 2017. Photograph by Maxime Fossat
Press release
Press release |
23 October 2018
Tuberculosis
Netherlands

MSF warns high prices of tuberculosis drugs restrict people's access to best drug-resistant TB treatment

5 min
Winile stands outside her house in the Manzini region of Swaziland Photograph by Alexis Huguet
Press release
Press release |
27 September 2018
Tuberculosis

MSF response to first-ever UN tuberculosis summit

2 min
MSF and other civil society protests in Munich at the European Patent Office against Gilead's monopoly on sofosbuvir, Germany 2018. Photograph by Peter Bauza
Press release
Press release |
26 September 2018
Hepatitis C
Brazil

Brazilian court suspends Gilead's patent on hepatitis C medicine sofosbuvir

2 min
A sputum sample analysis at the Blue House Clinic in Kenya, 2011. Photograph by Bruno De Cock
Press release
Press release |
25 September 2018
Tuberculosis

Global leaders must make bold commitments at first-ever UN tuberculosis summit

5 min
Kibera is one of the largest slums in Kenya. Here, MSF offers care to a neglected population isolated from basic healthcare standards due to hardships of poverty, Kenya 2011. Photograph by Bruno De Cock
Press release
Press release |
18 September 2018
Tuberculosis

MSF response to release of WHO’s Global Tuberculosis Report 2018

3 min
In March 2017, organisations from 17 European countries filed an opposition to Gilead Science's patent on the highly effective hepatitis C drug sofosbuvir. On 13th and 14th of September 2018, the hearing took e place before the European Patent Office in Munich. Photograph by Peter Bauza
Press release
Press release |
13 September 2018
Hepatitis C
Europe

MSF response to ruling in Gilead sofosbuvir patent hearing at European Patent Office

2 min
First set of free Hepatitis C medicines Sofosbuvir and Daclatasvir provided by Delhi Govt. run GB Pant hospital. Photograph by Garvit Nangia Photograph by Garvit Nangia
Press release
Press release |
11 September 2018
Hepatitis C
Europe

Civil society groups call for end to Gilead’s unwarranted hepatitis C drug monopoly in Europe

5 min
Emmanuel arrived at the Nsanje district hospital with advanced HIV and related opportunistic infections cryptococcal meningitis and TB. He underwent a lumbar puncture to evacuate fluid creating pressure in the spinal column and brain caused by cryptococcal meningitis, Malawi 2017. Photograph by Luca Sola
Press release
Press release |
30 August 2018
Tropical & neglected diseases
United States of America

FDA adds new diseases to list of those eligible for flawed government incentive

4 min
  • Load More
Navigate
  • About MSF Access
  • Contact us
  • Get involved
  • Our work
  • Resources
  • Search
Get updates
  • Sign up for our newsletter
  • Privacy & data protection information
Contact

MSF Access
Médecins Sans Frontières
140 Route de Ferney
1202 Geneva, Switzerland
Phone:+41 22 849 8484
E-mail: [email protected]

Follow us

  • X
  • Facebook
  • YouTube
  • Medium
Medicines Shouldn't Be A Luxury